- Home
- NUW vs ACRV Comparison
NUW vs ACRV Comparison
Compare NUW & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- ACRV
- Stock Information
- Founded
- NUW 2008
- ACRV 2018
- Country
- NUW United States
- ACRV United States
- Employees
- NUW N/A
- ACRV N/A
- Industry
- NUW Investment Managers
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- NUW Finance
- ACRV Health Care
- Exchange
- NUW Nasdaq
- ACRV Nasdaq
- Market Cap
- NUW 246.1M
- ACRV 247.8M
- IPO Year
- NUW N/A
- ACRV 2022
- Fundamental
- Price
- NUW $13.84
- ACRV $6.55
- Analyst Decision
- NUW
- ACRV Strong Buy
- Analyst Count
- NUW 0
- ACRV 5
- Target Price
- NUW N/A
- ACRV $22.40
- AVG Volume (30 Days)
- NUW 45.3K
- ACRV 46.3K
- Earning Date
- NUW 01-01-0001
- ACRV 11-13-2024
- Dividend Yield
- NUW 3.66%
- ACRV N/A
- EPS Growth
- NUW N/A
- ACRV N/A
- EPS
- NUW N/A
- ACRV N/A
- Revenue
- NUW N/A
- ACRV N/A
- Revenue This Year
- NUW N/A
- ACRV N/A
- Revenue Next Year
- NUW N/A
- ACRV N/A
- P/E Ratio
- NUW N/A
- ACRV N/A
- Revenue Growth
- NUW N/A
- ACRV N/A
- 52 Week Low
- NUW $12.45
- ACRV $3.19
- 52 Week High
- NUW $14.44
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- NUW 44.03
- ACRV 34.32
- Support Level
- NUW $13.71
- ACRV $6.11
- Resistance Level
- NUW $13.89
- ACRV $6.68
- Average True Range (ATR)
- NUW 0.15
- ACRV 0.49
- MACD
- NUW 0.00
- ACRV -0.20
- Stochastic Oscillator
- NUW 23.58
- ACRV 16.73
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.